BBOT
$9.48
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Intraday
Recent News
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners’ Global Healthcare Conference to outline its strategy around “next-generation RAS therapeutics,” highlighting three clinical-stage small-molecule programs and the company’s focus on achieving a high therapeutic ind